0 Replies
BOULDER, CO, May 25, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that its Director of Biology, Eva van Rooij, Ph.D., will give the keynote lecture at The Ohio State University College... Contine Reading & Discuss→
0 Replies
Stories include:
Starved of cash, Cambridge, MA-based Helicos BioSciences has cut its work force in half, laying off 40 people as it changes its focus to the diagnostics side of the business. The move earned a bit of respect on Wall Street, where its battered shares climbed 11 percent--to 62... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., May 17, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported its financial results for the quarter ended March 31, 2010. Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., May 11, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company’s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the 6th Annual... Contine Reading & Discuss→
0 Replies
Stories include:
FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 90,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!
About... Contine Reading & Discuss→
0 Replies
Download PDF
Paris, France and Hoersholm, Denmark/San Diego, California, June 4, 2010 - Red Herring announced its Top 100 Award Contine Reading & Discuss→
